Roche Discontinues Duchenne Hope At Interim Analysis
Anti-Myostatin Approach Disappoints Again
Roche is to discontinue its RG6206 clinical development program in Duchenne muscular dystrophy after an interim analysis of the Phase II/III SPITFIRE study indicates the compound would be “highly unlikely” to show a clinical benefit.
